Podcast Episodes
Back to Search
Episode 164: Every angle on the FDA's polarizing approval of Biogen's Alzheimer's drug
We're devoting this entire episode to the FDA's polarizing decision to approve Aduhelm, a controversial Biogen treatment for Alzheimer's disease. Fir…
5 years, 4 months ago
Episode 163: Marilynn Marchione on covering the CRISPR babies scandal
First, we discuss why it's so hard to predict FDA decisions, and why the latest big deal in biotech left investors cold. Then, STAT Washington corres…
5 years, 4 months ago
Episode 162: Scott Gottlieb on Covid and grilling, plus how Zolgensma has changed SMA
STAT's Andrew Joseph joins us to talk about the two-year anniversary of the approval of gene therapy Zolgensma and the effect it has had on families …
5 years, 5 months ago
Episode 161: Biotech meme stocks, the lessons of Spanish Flu, & becoming a pandemic celebrity
First, we discuss Ginkgo Bioworks, the multibillion-dollar biotech company with grand ambitions, a famous ticker symbol, and an affinity for memes. T…
5 years, 5 months ago
Episode 160: Global Covid-19 failures, a sluggish CDC, and a boisterous STAT Health Tech Summit
Can we prevent the next Covid-19? Has the CDC become too cautious? And how many sensors should be worn to bed? First, our colleague Helen Branswell j…
5 years, 5 months ago
Episode 159: Thomas Bollyky on patent waivers, plus vaccine riches, & a gene therapy for aging
First, Moderna and Pfizer are poised to make billions of dollars from their Covid-19 vaccines this year, and we discuss what that massive infusion of…
5 years, 5 months ago
Episode 158: Angela Rasmussen on Russia's vaccine controversy, plus Biden's drug pricing punt
First, STAT Washington correspondent Rachel Cohrs joins us to explain why President Biden's endorsement for drug pricing reform rang hollow to many a…
5 years, 6 months ago
Episode 157: Mercedes Carnethon on outdoor masking, FDA in limbo, & gene therapy's uncertain upside
First, Northwestern University epidemiologist Mercedes Carnethon joins us to weigh on the nation's latest Covid-19 debate: Is it OK to go maskless ou…
5 years, 6 months ago
Episode 156: J&J's vaccine pause, talking about remote risks, & why no new drugs for Covid-19
How do you describe a one-in-a-million risk? What's heparin-induced thrombocytopenia? And why's it so hard to find drugs for Covid-19? We cover all t…
5 years, 6 months ago
Episode 155: AstraZeneca's vaccine woes, compassionate use, & giving out Covid vaccines
What's next for AstraZeneca? Are there any right answers when it comes to compassionate use? And how does it feel to give someone a Covid-19 vaccine?…
5 years, 6 months ago